- Trial phase
- Approved (marketed); no pivotal-stage program pending for this molecule
- Time to market
- Already approved and marketed, subcutaneous Simponi approved in 2009 and the intravenous Simponi Aria form cleared FDA in July 2013 (per the recorded JNJ FDA-approval catalyst on 2013-07-18); no new approval pending for JNJ.
- Why 3/10
- Simponi is already approved and marketed with no pending JNJ regulatory decision in the next ~12 months, the closest dated event is Alvotech's expected late-2026 FDA decision on AVT05, a proposed golimumab biosimilar, which is a competitive threat to the franchise but not a JNJ catalyst, so the score stays at 3 (approved drug, minor asset inside a mega-cap portfolio).
There is no binary JNJ event tied to Simponi, watch instead for the FDA decision on Alvotech's AVT05 golimumab biosimilar (expected ~late 2026 after its June 2026 BLA resubmission and six-month review), which would accelerate erosion of Simponi sales. For JNJ stock, Simponi is a legacy anti-TNF line item; the real drivers are the broader pharma pipeline, and the stock currently trades around $262 with a mean analyst price target of $272.50 (implied upside ~6.7%).
Price Chart
Executive Summary
Simponi/Simponi Aria (golimumab) is Johnson & Johnson's Janssen-developed anti-TNF biologic, approved for several inflammatory conditions and recorded in SecBot's FDA-catalyst data with a July 18, 2013 approval event for the IV form. It is a mature, marketed asset inside a mega-cap whose whole thesis does not depend on it, JNJ trades near $262 with a buy-leaning analyst consensus (mean target $272.50). The most market-relevant near-term development is competitive, not company-driven: Alvotech (ALVO) resubmitted its AVT05 golimumab biosimilar BLA to the FDA in June 2026 with a decision expected late 2026, which would pressure Simponi's franchise.
How It Works
Simponi (golimumab) is an injectable biologic, a lab-made antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF), a protein that drives inflammation in autoimmune diseases. Blocking TNF dampens the joint and gut inflammation behind rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It comes as a self-injected shot (Simponi) and an IV infusion (Simponi Aria).
Trial Status
Golimumab is fully approved and commercialized. The only active JNJ-sponsored clinical work in the local pipeline database is a completed Phase 2 study (NCT05071664, 91 patients) of guselkumab + golimumab combination therapy in psoriatic arthritis, which finished primary completion May 2024 with results posted. The regulatory front is now on the biosimilar side: Alvotech resubmitted its AVT05 BLA (a proposed biosimilar to Simponi/Simponi Aria) to the FDA on June 4, 2026, with an expected six-month FDA review.
The Two-Sided Case
Upcoming Catalysts
- FDA decision on Alvotech's AVT05 golimumab biosimilar, expected ~late 2026 (six-month review of June 4, 2026 resubmission), a negative overhang for the Simponi franchise and a positive catalyst for ALVO
- JNJ quarterly earnings/immunology sales disclosures for golimumab (next reports follow the 10-Q cadence; latest 10-Q filed 2026-07-23)
- Any JNJ label or pediatric/indication updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report